quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:26·21d
SECFiling
Kyverna Therapeutics Inc. logo

SEC Form EFFECT filed by Kyverna Therapeutics Inc.

KYTX· Kyverna Therapeutics Inc.
Health Care
Original source

Companies

  • KYTX
    Kyverna Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Aug 20UpdateWilliam Blair-
  • May 27UpdateH.C. Wainwright$5.00
  • Oct 10UpdateUBS$13.00
  • Oct 9UpdateRodman & Renshaw$16.00
  • Jul 3UpdateH.C. Wainwright$8.00
  • Mar 4UpdateMorgan Stanley$40.00

Related

  • SEC1d
    Kyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • SEC2d
    Kyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR2d
    Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
  • SEC3d
    Kyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR3d
    Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
  • SEC10d
    SEC Form DEFA14A filed by Kyverna Therapeutics Inc.
  • SEC10d
    SEC Form DEF 14A filed by Kyverna Therapeutics Inc.
  • PR14d
    Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022